e-lek
[Top] [All Lists]

[e-lek] Fwd: [e-drug] Independent Drug and Healthcare Newsletter for May 2019

---------- Forwarded message ---------
From: Prescrire International <international@prescrire.org>
Date: Fri, 3 May 2019 at 01:46
Subject: [e-drug] Independent Drug and Healthcare Newsletter for May 2019
To: e-drug@healthnet.org <e-drug@healthnet.org>


E-DRUG: Independent Drug and Healthcare Newsletter for May 2019
-----------------------------------------------------------------------------------

Newsletter, May 2019
Independent Drug & Healthcare Newsletter from the non-profit journal
Prescrire International

> View the contents
http://english.prescrire.org/en/SummaryDetail.aspx?Issueid=204

If your friends or colleagues would be interested, forward this email and
invite them to sign up for the free Newsletter.
http://english.prescrire.org/en/83/552/0/0/About.aspx

Like what you see?
Subscribe to Prescrire International
http://english.prescrire.org/en/83/178/0/0/About.aspx

In Prescrire's Spotlight this month
--------------------------------------------------------------------------------
FEATURED REVIEW
Drug-induced retinal disorders
Retinal damage can cause different types of visual disturbances, of varying
severity. Many drugs can provoke retinal disorders. What are the underlying
mechanisms? Which drugs are responsible?
> Read more
https://english.prescrire.org/en/81/168/57293/0/NewsDetails.aspx
--------------------------------------------------------------------------------

FREE DOWNLOAD
In the May issue of Prescrire International: Dupilumab (Dupixent°) in
adults with atopic dermatitis
Dupilumab (Dupixent°), a monoclonal antibody, is an option for very
troublesome eczema after failure of ciclosporin. Full text available for
free download.
> Read more
https://english.prescrire.org/en/81/168/57292/0/NewsDetails.aspx
--------------------------------------------------------------------------------

SUBSCRIBE NOW
Subscribe today for full access to top-quality content from Prescrire
International
Enjoy access to subscriber-only content available on our website, including
every article published in Prescrire International since 1992. Prices for a
one-year subscription start at 150 euros (less for students and residents
of lower-income countries).
>Subscribe now
https://english.prescrire.org/en/83/178/0/0/About.aspx
--------------------------------------------------------------------------------

Vaccine hesitancy: understand it better, to provide better support
Rather than considering people reluctant to vaccinate as irresponsible, it
is better to try to restore confidence by improving public knowledge,
identifying the barriers and seeking ways to overcome them.
> Read more
https://english.prescrire.org/en/81/168/57295/0/NewsDetails.aspx
--------------------------------------------------------------------------------

Drugs for Alzheimer's disease: reduction in the number of prescriptions is
too slow
A study conducted by the independent French medical journal Prescrire shows
a reduction of only around 26% in the number of patients in France exposed
to at least one Alzheimer's disease drug between 2012 and 2017. In
approximately 3 out of 4 newly exposed patients, treatment lasted for more
than 6 months, despite the proven harms.
> Read more
https://english.prescrire.org/en/81/168/57296/0/NewsDetails.aspx
--------------------------------------------------------------------------------

Methylphenidate (Ritalin°) as a means of controlling classroom behaviour
Too many children are overdiagnosed with attention deficit hyperactivity
disorder (ADHD) simply because they are the youngest in the class and so
tend to be more easily distracted and disruptive.
> Read more
https://english.prescrire.org/en/81/168/57294/0/NewsDetails.aspx
--------------------------------------------------------------------------------

ADVANCING HEALTHCARE POLICY
The use of "big data" in the authorisation and supervision of health
products must rely on facts, trustworthy evidence and transparency
In its response to the public consultation on big data organised by the
HMA-EMA Joint Big Data Taskforce, Prescrire considers that regulation on
the authorisation and supervision of health products cannot be based on
hope and promises but needs to rely on facts, trustworthy evidence and
transparency.
> Read more
https://english.prescrire.org/en/79/207/46302/6002/5953/SubReportDetails.aspx
-------------------------------------------------------------------------------

COMING SOON
Enjoy these features, and more, in our upcoming issues
Ruxolitinib in myelofibrosis * Methylphenidate during pregnancy:
teratogenic and fetotoxic, with concerns about long-term effects * Ginkgo
biloba: seizures * Oral anticoagulants in atrial fibrillation * Talking to
patients about risks: strategies for better communication...
>Subscribe now
https://english.prescrire.org/en/83/178/0/0/About.aspx

Share this with a friend or colleague: Forward this email

Prescrire International <international@prescrire.org>
_______________________________________________
E-Drug, an e-forum on essential drugs, is moderated by a team of
international experts and hosted by FHI 360

To subscribe:  e-drug-join@healthnet.org
To unsubscribe:  e-drug-leave@healthnet.org
To discuss (subscribers only):  e-drug@healthnet.org
For help:  e-drug-owner@healthnet.org
For archives:  http://lists.healthnet.org/archive/html/e-drug/
<Prev in Thread] Current Thread [Next in Thread>
  • [e-lek] Fwd: [e-drug] Independent Drug and Healthcare Newsletter for May 2019, Liliya Eugenevna Ziganshina <=